pimobendan

01/01/1997 - "In a multicentre, placebo-controlled, double-blind trial, 8 weeks of treatment with pimobendan 2.5 mg b.i.d., which was suggested to be the optimal dose in a preceding dose-finding study, definitely improved symptoms and signs of heart failure in 52.6% of patients, and New York Heart Association function class in 64.1% of patients. "
05/01/2002 - "Overall, 8 of 10 animals in the pimobendan-treated group, and 1 of 10 animals in the placebo group improved their heart failure status by at least I modified New York Heart Association functional class after initial stabilization (P = .005, Fisher's exact test). "
01/01/2022 - "Pimobendan is widely used for the treatment of dogs with heart failure via the oral route. "
02/01/2020 - "Although all of the patients at the time of administration of pimobendan were NYHA class III or IV with repeated hospitalization for heart failure, pimobendan seemed to be effective for improving symptoms and enabling patients to be discharged and receive outpatient medical care. "
11/01/2016 - "Pimobendan is effective in treatment of dogs with congestive heart failure (CHF) secondary to myxomatous mitral valve disease (MMVD). "

01/01/2012 - "Pimobendan (Vetmedin) is an effective treatment for canine chronic degenerative mitral valve disease and dilated cardiomyopathy. "
05/01/2015 - "A knock-in mouse model of human genetic dilated cardiomyopathy, which shows a clear transition from compensatory to end-stage HF at a fixed time during growth, was used to evaluate the efficacy of pimobendan and explore the underlying molecular and cellular mechanisms. "
05/01/2002 - "A double-blind, randomized, placebo-controlled study of pimobendan in dogs with dilated cardiomyopathy."
07/01/2023 - "MANAGEMENT OF SUSPECTED DILATED CARDIOMYOPATHY WITH PIMOBENDAN IN TWO LEOPARD SHARKS (TRIAKIS SEMIFASCIATA)."
11/01/2012 - "The benefit of pimobendan in delaying the progression of preclinical dilated cardiomyopathy (DCM) in Dobermans is not reported. "

10/01/2021 - "Further studies are needed to determine whether pimobendan has similar effects in cats with cardiac diseases."
11/01/2023 - "To determine if dog characteristics such as age, breed, body condition score, ACVIM stage of heart disease or biochemical laboratory value alter the pharmacokinetics of orally administered pimobendan and its metabolite in a cohort of dogs with naturally occurring MMVD. "
12/08/2018 - "Is treatment with pimobendan associated with an increased risk of arrhythmias in dogs with heart disease?"
07/01/2012 - "Information on medical history, laboratory results, diagnostic imaging findings, treatments received, and survival time were obtained from medical records of cats that received pimobendan because of cardiac disease. "
12/01/2011 - "Pimobendan appears to be well tolerated in cats with advanced heart disease when used with a variety of concurrent medications. "

08/01/1997 - "These results indicate that pimobendan may be useful in the treatment of patients with secondary pulmonary hypertension."
12/01/2020 - "Acute effects of intravenous pimobendan administration in dog models of chronic precapillary pulmonary hypertension."
01/01/2012 - "Compounded pimobendan for canine chronic degenerative mitral valve disease and pulmonary hypertension."
01/01/2012 - "In this report, we describe the effects of a palatable customized oral form of pimobendan used with both compounded and commercially manufactured conventional drug therapy to treat degenerative mitral valve disease and pulmonary hypertension in two small dogs. "
08/01/1997 - "We studied the clinical usefulness of single oral doses of pimobendan (2.5 mg) in 8 patients with pulmonary hypertension caused by chronic pulmonary emphysema. "

02/23/2021 - "Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy."
01/01/2019 - "However, use of pimobendan remains controversial in cats with hypertrophic cardiomyopathy (HCM) due to lack of pharmacodynamic data for pimobendan in cats with HCM and due to theoretical concerns for exacerbating left ventricular outflow tract obstructions. "
01/01/2019 - "Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study."
02/23/2021 - "Prior studies have suggested that pimobendan is associated with several positive effects in cats, including improved survival in cats with congestive heart failure and improved left atrial function in research colony cats with hypertrophic cardiomyopathy (HCM) and normal cats. "
03/01/2021 - "Effects of pimobendan in cats with hypertrophic cardiomyopathy and recent congestive heart failure: Results of a prospective, double-blind, randomized, nonpivotal, exploratory field study."